The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE
JB Rottman, T Smith, JR Tonra, K Ganley, T Bloom… - Nature …, 2001 - nature.com
JB Rottman, T Smith, JR Tonra, K Ganley, T Bloom, R Silva, B Pierce, JC Gutierrez-Ramos…
Nature immunology, 2001•nature.comThe inducible costimulatory molecule (ICOS) is expressed on activated T cells and
participates in a variety of important immunoregulatory functions. After the induction of
experimental allergic encephalomyelitis in SJL mice with proteolipid protein (PLP), brain
ICOS mRNA and protein were up-regulated on infiltrating CD3+ T cells before disease
onset. ICOS blockade during the efferent immune response (9–20 days after immunization)
abrogated disease, but blockade during antigen priming (1–10 days after immunization) …
participates in a variety of important immunoregulatory functions. After the induction of
experimental allergic encephalomyelitis in SJL mice with proteolipid protein (PLP), brain
ICOS mRNA and protein were up-regulated on infiltrating CD3+ T cells before disease
onset. ICOS blockade during the efferent immune response (9–20 days after immunization)
abrogated disease, but blockade during antigen priming (1–10 days after immunization) …
Abstract
The inducible costimulatory molecule (ICOS) is expressed on activated T cells and participates in a variety of important immunoregulatory functions. After the induction of experimental allergic encephalomyelitis in SJL mice with proteolipid protein (PLP), brain ICOS mRNA and protein were up-regulated on infiltrating CD3+ T cells before disease onset. ICOS blockade during the efferent immune response (9–20 days after immunization) abrogated disease, but blockade during antigen priming (1–10 days after immunization) exacerbated disease. Upon culture with PLP and compared with immunized controls, splenocytes produced either decreased interferon-γ (IFN-γ, in efferent blockade) or excessive IFN-γ (in priming blockade). PLP-specific immunoglobulin G1 was decreased in animals treated with anti-ICOS during antigen priming, but not in other groups.
nature.com